Posted by Michael Wonder on 28 Nov 2019
Which drug prices should Medicare negotiate? A “too little” or “too late” approach
28 November 2019 - By negotiating prices only for drugs that have too little evidence to support full approval or are too late in their life cycle to justify continued high prices, Medicare could both deliver substantial savings and preserve the incentive framework for innovation.
